NatWest share price hits fresh 52-week high after buyback update — what investors watch next
6 January 2026
1 min read

NatWest share price hits fresh 52-week high after buyback update — what investors watch next

London, Jan 6, 2026, 09:04 GMT — Regular session

NatWest Group (NWG.L) shares hit a fresh 52-week high on Tuesday and were up about 0.6% at 669.6 pence in London trade, after touching 674.2 pence earlier in the session. The stock traded between 665.2 pence and 674.2 pence, versus a prior close of 665.6 pence. 1

The move keeps the focus on shareholder returns and on how UK-focused lenders are holding up as investors parse domestic credit demand. A run of small, steady repurchases can help underpin the share price by reducing the share count, even when the daily volumes look modest.

NatWest has set its full-year 2025 results for Feb. 13, when it plans to introduce guidance for 2026 and new targets for 2028. That makes the next few weeks a reset point for expectations on margins, costs and capital returns. 2

The bank said it bought back 806,867 ordinary shares on Jan. 5 at a volume-weighted average price of 664.25 pence, with purchases ranging from 654.80 pence to 668.40 pence. The shares will be cancelled, NatWest said, and it will hold 220,742,145 shares in treasury after settlement. 3

Macro data also stayed in the spotlight for UK lenders. Bank of England figures showed net consumer borrowing rose by 2.08 billion pounds in November, the biggest increase since November 2023, while mortgage approvals dipped to 64,530; “This also suggests there isn’t much scope for a pick-up in consumer spending in 2026,” Alex Kerr, UK economist at Capital Economics, said. 4

For NatWest, which has a large UK retail footprint, the mix of borrowing, mortgage activity and household spending matters on two fronts: loan growth and credit quality. Investors also watch net interest margin — the gap between what a bank earns on loans and pays on deposits — because it drives a large share of earnings.

Broader sector calls added a tailwind. Goldman Sachs on Tuesday lifted its 12-month target for Europe’s STOXX 600 and upgraded the financial services sector to “overweight”, meaning it expects the group to outperform the wider market. 5

Technicians are watching whether NatWest can hold above the mid-660s after the latest push to new highs. The buyback’s average purchase price sits just below current levels, offering a nearby reference point for traders looking for support.

The risk is that tougher competition in mortgages and deposits compresses pricing, or that a softer consumer backdrop turns the recent rise in borrowing into higher impairments. Either would blunt the earnings uplift investors typically expect from buybacks.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
National Grid plc share price ticks up as UK power-grid hiring boom keeps utilities in focus
Previous Story

National Grid plc share price ticks up as UK power-grid hiring boom keeps utilities in focus

BAT stock steadies after fresh buyback disclosure as February results near
Next Story

BAT stock steadies after fresh buyback disclosure as February results near

Go toTop